Q2 FY2026 EarningsQ2 FY26 results beat consensus on top and bottom lines: collaboration revenue was $3.17M vs. $4.56M expected (miss), but GAAP EPS of -$0.40 significantly outperformed the -$0.50 consensus. The net loss narrowed to $24.5M from $33.4M YoY, driven by a 30% reduction in operating expenses following 2025 restructuring. Management confirmed a cash runway into 2028, supported by a $148.8M liquidity position and ongoing partner reimbursements.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Voyager Therap(VYGR) the Revenue is 3.165 M (-39.13%), Miss estimate;the EBIT is -26.39 M (+27.94%), Beat estimate;the EPS is -0.4 (+29.82%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B39.13%
0.00B12.25%
-0.00B26.88%
EBITExceed expectations
-0.03B27.94%
-0.03B11.44%
+0.01B16.50%
EPSExceed expectations
-0.429.82%
-0.50112.11%
+0.101017.71%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf